Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure"

Transcription

1 Intravesical Gemcitabine for High Risk, Nonmuscle Invasive Bladder Cancer after Bacillus Calmette-Guerin Treatment Failure Itay A. Sternberg, Guido Dalbagni,* Ling Y. Chen, Sherri M. Donat, Bernard H. Bochner and Harry W. Herr From the Urology Service, Department of Surgery (IAS, GD, SMD, BHB, HWH) and Department of Epidemiology and Biostatistics (LYC), Memorial Sloan-Kettering Cancer Center, New York, New York Abbreviations and Acronyms BCG ¼ bacillus Calmette-Guerin CIS ¼ carcinoma in situ CR ¼ complete response CSS ¼ cancer specific survival MIBC ¼ muscle invasive bladder cancer NMIBC ¼ nonmibc NR ¼ no response OS ¼ overall survival PFS ¼ progression-free survival PR ¼ partial response RFS ¼ recurrence-free survival Accepted for publication April 29, Study received institutional review board approval. Supported by the Sidney Kimmel Center for Prostate and Urologic Cancers. * Correspondence: Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, New York (telephone: ; FAX: ; For another article on a related topic see page Purpose: We report our experience with intravesical gemcitabine for bladder cancer after failed bacillus Calmette-Guerin treatment. Materials and Methods: We retrospectively reviewed the records of patients at our cancer center treated with intravesical gemcitabine after bacillus Calmette- Guerin failure. We estimated progression-free, recurrence-free and cancer specific survival using the cumulative incidence function, considering death from another cause as a competing risk. Comparisons were made using the Gray test. Overall survival was estimated using the Kaplan-Meier method and differences were compared with the log rank test. Results: Of 69 patients treated with intravesical gemcitabine 37 had bacillus Calmette-Guerin refractory disease. Median followup in progression-free patients was 3.3 years. Progression-free and cancer specific survival were similar in patients with refractory disease and those with other types of bacillus Calmette- Guerin failure. Overall survival was lower in patients with refractory disease (58% vs 71%) but this was not statistically significant (p ¼ 0.096). Of the patients 27 patients experienced a complete response. Progression-free, cancer specific and overall survival did not differ significantly between patients with and without a complete response. Cystectomy was subsequently performed in 20 patients. Those with a complete response had a delayed time to cystectomy and no muscle invasive bladder cancer at cystectomy. There were no serious adverse events and only a minority of patients discontinued treatment due to adverse events. Conclusions: In our experience intravesical gemcitabine should be considered after bacillus Calmette-Guerin failure in patients with bladder cancer who refuse radical cystectomy or who are not candidates for major surgery. Key Words: urinary bladder, urinary bladder neoplasms, BCG vaccine, treatment failure, gemcitabine BCG is considered the most effective intravesical agent for NMIBC and it is recommended for patients at high risk for progression. 1 BCG decreases the risk of recurrence, the development of distant metastasis, and the risk of death and bladder cancer related death compared to intravesical chemotherapy. 2 Failure to achieve a CR after an induction course of BCG or recurrence after BCG treatment is associated with an increased risk of disease progression and poor prognosis. 3,4 Standard treatment after BCG failure is radical cystectomy. Patients 1686 j /13/ /0 THE JOURNAL OF UROLOGY 2013 by AMERICAN UROLOGICAL ASSOCIATION EDUCATION AND RESEARCH,INC. Vol. 190, , November 2013 Printed in U.S.A.

2 GEMCITABINE FOR BLADDER CANCER AFTER BACILLUS CALMETTE-GU ERIN FAILURE 1687 who are not candidates for or who are unwilling to undergo cystectomy have limited options. 1 Intravesical valrubicin was approved by the United States Food and Drug Administration for BCG refractory bladder CIS. Several other intravesical therapies were also studied in patients with NMIBC who experience BCG failure, including immunotherapy, chemotherapy and thermochemotherapy. 5,6 Gemcitabine is a deoxycytidine with a broadspectrum antitumor effect. It is used in neoadjuvant and adjuvant settings in combination with other chemotherapeutic drugs for MIBC, and for advanced and metastatic tumors We previously reported the results of phase I and II studies of intravesical gemcitabine in patients after BCG failure. 13,14 In the current study we report our experience with intravesical gemcitabine after BCG failure. We explored the effect of the type of BCG failure on the patient response to gemcitabine and compared patient outcomes by the response to gemcitabine treatment. PATIENTS AND METHODS After obtaining institutional review board approval, we retrospectively reviewed the charts of patients treated with intravesical gemcitabine for NMIBC at our institution between January 1999 and October We identified 69 patients with NMIBC who were treated with intravesical gemcitabine after BCG treatment failed. BCG Failure A patient was considered to have BCG refractory disease when there was failure to achieve a disease-free state 6 months after initial BCG therapy with maintenance or retreatment at 3 months due to a persistent or rapidly growing recurrent tumor. BCG resistant disease was defined as recurrence 3 months after an induction cycle. BCG relapsing disease was defined as disease recurrence after the patient was disease-free for 6 months. BCG intolerant disease was defined as recurrence after administering a less than adequate course of therapy due to a serious adverse event or symptomatic intolerance requiring the discontinuation of BCG therapy. 15 Intravesical Gemcitabine Treatment Patients received 2 courses of intravesical gemcitabine twice weekly for 3 weeks with courses separated by a week of rest for a total of 12 instillations. Intravesical gemcitabine was given at a dose of 2,000 mg instilled in 100 ml saline. Patients were instructed to hold the instillation for 60 minutes. Responses to intravesical gemcitabine treatment were divided into 3 categories, including 1) CR when no tumor was seen 3 months after treatment and the patient had negative cytology results, 2) PR when no tumor was seen at 3 months but the patient had positive cytology results, and 3) NR when there was a viable tumor 3 months after treatment. Toxicity was assessed after each treatment and reported using National Cancer Institute (NCI) Common Toxicity Criteria (CTC), version 2.0. Statistical Analysis Separate analyses were done for OS, PFS, RFS and CSS. Progression was defined as progression to MIBC or the appearance of metastasis. Recurrence was defined as any recurrent bladder cancer. Kaplan-Meier curves were calculated to determine the difference in OS between patients with BCG refractory disease vs other types of BCG failure and compared with the log rank test. PFS, RFS and CSS were estimated using the cumulative incidence function, considering death from another cause as a competing risk, with comparisons made using the Gray test. The HR and 95% CI were estimated using a Cox proportional hazard model for OS and competing risk analysis for PFS, RFS and CSS. Survival was calculated from the date of BCG failure. We also analyzed PFS, CSS and OS by the response to gemcitabine therapy (CR vs PR and NR). Separate analyses were done for PFS, CSS and OS using the Kaplan-Meier method and the cumulative incidence function, as described. Landmark analysis was performed using a landmark time of 5 months after the date of gemcitabine initiation to ascertain the response to gemcitabine. Patients were evaluated 1 to 3 weeks after completing treatment. Given the absence of a clinically significant landmark, we chose 5 months as the landmark since this was the time point that excluded the fewest patients. Two patients who responded after the landmark as well as 3 lost to followup, 1 with progression and 1 who died before the landmark were excluded from PFS analysis. For CSS and OS analysis 2 patients who responded after the landmark and 3 lost to followup before the landmark were excluded. Statistical analysis was done using StataÒ 12 and R (R Foundation for Statistical Computing, Vienna, Austria) with the cmprsk package. RESULTS Between 1999 and 2011 at our institution 69 patients were treated with intravesical gemcitabine for NMIBC after BCG treatment failed. All patients were offered cystectomy, of whom 5 were not candidates for major surgery, 63 were interested in bladder sparing alternatives and 1 was treated after cystectomy was abandoned due to concern over injuring a single pelvic kidney. Table 1 lists study cohort descriptive characteristics. Therapy was done in 37 (54%) of the 69 patients for BCG refractory disease, in 5 (7%) for BCG resistant disease, in 20 (29%) for BCG recurrent disease and in 5 (7%) for BCG intolerant disease. The reason for BCG failure could not be determined in 2 patients due to insufficient data. There was no great difference between patients with BCG refractory disease and those with another type of BCG failure. However, patients with refractory disease were more likely to have had CIS before BCG (41% vs 29%). At last followup 11 patients had progressed, 10 had died of bladder cancer and 13 had died of another cause. Median followup was 3.3 years in

3 1688 GEMCITABINE FOR BLADDER CANCER AFTER BACILLUS CALMETTE-GU ERIN FAILURE Table 1. Patient characteristics BCG Refractory Other BCG Failure* No. pts Median age at BCG failure (IQR) 71 (63e75) 73 (63e77) No. male (%) 27 (73) 26 (81) No. stage before BCG treatment (%): Ta 19 (51) 17 (55) CIS 15 (41) 9 (29) T1 3 (8) 5 (16) No. high grade before BCG treatment (%) 34 (92) 24 (86) No. stage at BCG failure (%): Ta 7 (19) 10 (33) Ta þ CIS 7 (19) 1 (3) T1 1 (3) 2 (7) T1 þ CIS 2 (5) 3 (10) CIS 20 (54) 14 (47) No. high grade at BCG failure (%) 37 (100) 28 (88) No. reason for deferring cystectomy (%): Patient unwilling 34 (92) 29 (91) Medically unfit 3 (8) 2 (6) Other 0 1 (3) Median No. recurrences after 1 (0e2) 1 (0e3) gemcitabine/pt (IQR) No. further intravesical treatment after 13 (35) 12 (38) gemcitabine (%) No. radical cystectomy (%) 12 (32) 8 (25) * BCG resistant, recurrent, intolerant or unknown due to insufficient data. progression-free patients and 3.6 years in diseasefree patients. Five-year OS was lower in patients with BCG refractory disease than in patients with another type of BCG failure but this was not statistically significant (58% vs 71%, log rank test p ¼ 0.096). Patients with BCG refractory disease were at twice the risk of death from any cause but this was not statistically significant (HR 2.05, 95% CI 0.87e4.84, p ¼ 0.1). Figure 1 shows the OS Kaplan- Meier curve. PFS, CSS and RFS did not differ significantly between patients with BCG refractory disease and those with another type of BCG failure (p ¼ 0.9, 0.7 and 0.2, respectively). The cumulative 5-year incidence of progression was 19% for BCG refractory disease and 22% for other types of BCG failure (HR 1.09, 95% CI 0.34e3.50). A similar cumulative incidence estimate with a wide CI was observed for CSS (HR 1.41, 95% CI 0.41e4.81). Survival analysis in patients with CIS at BCG failure showed results similar to those of the entire cohort. There was no significant difference in PFS, CSS or OS between patients with BCG refractory CIS and patients with other types of BCG failure (log rank test p ¼ 0.2, 0.3 and 0.2, respectively). Figure 2 shows the CSS Kaplan-Meier curve. Median time from BCG failure to the initiation of intravesical gemcitabine therapy was 8.1 weeks. The full treatment course was completed as planned in 61 patients (88%), while treatment was stopped prematurely in only 8 due to adverse events. After gemcitabine treatment, 27 patients had CR, 19 had PR and 20 had NR. Three patients could not be evaluated for a response to treatment due to insufficient data. The 5-year cumulative incidence of death from bladder cancer was 12% (95% CI 2e31) and 18% (95% CI 7e34) in patients with and without a CR, respectively. Figure 3 shows cumulative incidence curves. There was no statistically significant difference in PFS, CSS or OS between patients with vs without a CR (p ¼ 0.3, 0.3 and 0.8, respectively). Figure 4 shows the cumulative incidence of recurrent bladder cancer. Of the 46 patients who experienced recurrence after intravesical gemcitabine treatment 18 underwent cystectomy. Another 2 patients underwent cystectomy after intravesical gemcitabine was prematurely discontinued due to adverse events. Of these 20 patients 18 initially refused cystectomy to Survival probability Cancer specific survival probability Time from BCG failure (yrs) Time from BCG failure (yrs) Number at risk Other types of BCG failure BCG refractory Number at risk Other types of BCG failure BCG refractory Figure 1. Kaplan-Meier curve of OS by type of BCG failure. Solid curve indicates BCG refractory disease. Dashed curve indicates other type. Figure 2. Kaplan-Meier curve of CSS in 47 patients with CIS by type of BCG failure. Solid curve indicates BCG refractory disease. Dashed curve indicates other type.

4 GEMCITABINE FOR BLADDER CANCER AFTER BACILLUS CALMETTE-GU ERIN FAILURE 1689 Cumulative Incidence Time from 5 months post gemcitabine initiation (years) Figure 3. Cumulative incidence curves of death from bladder cancer by response to intravesical gemcitabine. Solid curve indicates PR plus NR. Dashed curve indicates CR. pursue bladder preservation but they elected cystectomy after the condition progressed or recurred to high grade disease. Two patients were initially evaluated to be unfit for major surgery. One underwent aortic valve replacement and coronary artery bypass grafting in the interim, and his risk decreased. The other patient was evaluated again after gemcitabine failed and was found to be at moderate risk for surgery. The remaining 28 patients continued to refuse cystectomy or were not candidates for major surgery. Of these patients 19 were treated with additional intravesical agents (further intravesical gemcitabine in 5, BCG with or without interferon in 13 and intravesical mitomycin C in 3 with more than 1 agent in some patients), while for 9 patients no further treatment was documented in the medical records. Of the 20 patients who underwent cystectomy the surgery was done in 17 for NMIBC and in 3 for progression to MIBC. Ten of these patients had a CR to intravesical gemcitabine and 10 did not. Median time from intravesical gemcitabine therapy to cystectomy was 8.5 months in the entire cohort, including 20.9 and 5.3 months in patients with and without a CR, respectively. No patient with a CR had MIBC at cystectomy. In 1 patient treated with cystectomy after a CR metastasis developed 28 months after cystectomy. The patient died of bladder cancer. Patients generally tolerated intravesical gemcitabine well. According to Common Terminology Criteria for Adverse Events (CTCAE), there were no life threatening events or treatment related deaths (grade 4 or 5) (table 2). Adverse events were reported in 49 patients (71%) and most were mild or moderate (CTCAE grade 1 or 2). The most common mild and moderate adverse events reported were urinary symptoms in 25 cases and fatigue in 24. Of the patients 12% experienced moderately severe adverse events (CTCAE grade 3) that required discontinuation of therapy, including urinary symptoms in 3, infection in 2 and skin rash, deep vein thrombosis and thrombocytopenia in 1 each. DISCUSSION The safety and efficacy of intravesical gemcitabine therapy were previously demonstrated in phase I and II studies with a CR rate of 23% to 56%. 13,14,16e20 Most patients enrolled in these studies were previously treated with BCG. Intravesical gemcitabine instillation immediately postoperatively was also reported to be safe but with no proven RFS advantage. 21 Table 2. Adverse events reported after intravesical gemcitabine therapy Adverse Event* No. Grade 1 or 2 (%) No. Grade 3 (%) Figure 4. Cumulative incidence curves of recurrent bladder cancer by response type, excluding 25 patients with recurrence before 5-month landmark. Solid curve indicates CR. Dashed curve indicates NR plus PR. Urinary 25 (36) 3 (4) Fatigue 24 (35) 0 Diarrhea 7 (10) 0 Hematuria 5 (7) 0 Skin rash 6 (9) 1 (1) Nausea 4 (6) 0 Fever 2 (3) 0 Constipation 2 (3) 0 Pulmonary 2 (3) 0 Urinary tract infection 0 1 (1) Deep vein thrombosis 0 1 (1) Infection 0 2 (2) Thrombocytopenia 0 1 (1) * Including only adverse events in 2 or more patients and grade 3 events according to NCI CTC. Including irritative symptoms, urgency, frequency, dysuria and bladder outlet obstruction.

5 1690 GEMCITABINE FOR BLADDER CANCER AFTER BACILLUS CALMETTE-GU ERIN FAILURE A recent report of the ongoing SWOG S0353 trial, in which intravesical gemcitabine was administered after BCG failure, described outcomes in 47 treated patients with a followup of at least 12 months. 22 The CR rate was similar to that in our series (45% and 39%, respectively) and 62% of the patients with CR were disease free at 12 months. We report one of the largest series of patients with NMIBC treated with intravesical gemcitabine after failed BCG therapy. We saw indications that intravesical gemcitabine resulted in a lower survival probability in patients with BCG refractory disease than in those with another type of BCG failure, although this was not statistically significant. However, about 80% of patients treated with intravesical gemcitabine remained free of progression for 5 years regardless of the type of BCG failure, which is a higher rate than previously reported. 4 Thus, we saw no reason to suggest that the indication for intravesical gemcitabine depends on the type of BCG failure. Nevertheless, the heterogeneity of patients with another type of BCG failure could have impacted the lack of difference between the 2 groups. Huguet et al reported that patients treated with cystectomy for NMIBC after BCG failure fared worse if cancer was up-staged to MIBC at cystectomy (5-year CSS 38% vs 90%). 23 In our cohort no patient with CR was up-staged at cystectomy and overall only 15% treated with radical cystectomy after intravesical gemcitabine had MIBC. Moreover, in our study patients who received intravesical gemcitabine had a 5-year CSS rate of about 85%, similar to the rate reported by Huguet et al in patients who were not up-staged at cystectomy, regardless of the response to intravesical gemcitabine. This observation may merely reflect the selection of patients for intravesical gemcitabine but it may also reflect the efficacy of this treatment. In patients who underwent cystectomy after intravesical gemcitabine failed an advantage of achieving a CR to intravesical gemcitabine was longer time to cystectomy (20.9 vs 5.3 months). However, this should be viewed with caution since all patients in our cohort initially refused or were unfit for cystectomy. Thus, those who underwent cystectomy after intravesical gemcitabine represent a select patient group. Since none of these patients had MIBC at surgery, the longer time to cystectomy can be attributable to the effect of intravesical gemcitabine and should be considered an advantage rather than a delay in recognizing the need for cystectomy. It is also plausible that a CR to gemcitabine reflects less aggressive disease. Whether it was a treatment effect or less aggressive disease, patients with a CR to gemcitabine can probably be followed, while those who do not achieve a CR should probably be counseled to consider cystectomy. Our study also shows that intravesical gemcitabine is safe and well tolerated. Of the patients 88% completed the treatment protocol and 29 of the 69 did not experience an adverse event. Most adverse events experienced by the others were grade 1 or 2. Only 12% of patients had grade 3 adverse events and none had a grade 4 or 5 adverse event. While this is a retrospective study with a relatively small cohort and no comparison arm with standard treatment, its main strength is its homogenous cohort composed entirely of patients previously treated with BCG, of whom 54% had BCG refractory disease. CONCLUSIONS In our experience intravesical gemcitabine should be considered after BCG failure in patients with NMIBC who refuse radical cystectomy or are not candidates for major surgery. We found no indication to suggest that the efficacy of intravesical gemcitabine depends on the type of BCG failure. In patients who eventually elected cystectomy after intravesical gemcitabine treatment an advantage of achieving a CR was longer time to cystectomy and lack of progression to MIBC. REFERENCES 1. Babjuk M, Oosterlinck W, Sylvester R et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: Sylvester RJ, Brausi MA, Kirkels WJ et al: Long-term efficacy results of EORTC Genito- Urinary Group randomized phase 3 study comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010; 57: Zlotta AR, Fleshner NE and Jewett MA: The management of BCG failure in non-muscleinvasive bladder cancer: an update. Can Urol Assoc J, suppl., 2009; 3: S Lerner SP, Tangen CM, Sucharew H et al: Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol 2009; 27: Barlow LJ, Seager CM, Benson MC et al: Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG. Urol Oncol 2010; 28: Yates DR and Roupret M: Contemporary management of patients with high-risk nonmuscle-invasive bladder cancer who fail intravesical BCG therapy. World J Urol 2011; 29: Dash A, Pettus JA 4th, Herr HW et al: A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience. Cancer 2008; 113: 2471.

6 GEMCITABINE FOR BLADDER CANCER AFTER BACILLUS CALMETTE-GU ERIN FAILURE Jin JO, Lehmann J, Taxy J et al: Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clin Genitourin Cancer 2006; 5: Lorusso V, Pollera CF, Antimi M et al: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34: Meliani E, Lapini A, Serni S et al: Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Toxicity evaluation. Urol Int 2003; 71: Scosyrev E, Messing EM, van Wijngaarden E et al: Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer 2012; 118: Shelley M, Cleves A, Wilt TJ et al: Gemcitabine for unresectable, locally advanced or metastatic bladder cancer. Cochrane Database Syst Rev 2011; 4: CD Dalbagni G, Russo P, Sheinfeld J et al: Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002; 20: Dalbagni G, Russo P, Bochner B et al: Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006; 24: Lerner SP, Schoenberg MP and Sternberg CN: Textbook of Bladder Cancer. Abingdon, United Kingdom: Taylor & Francis Witjes JA, van der Heijden AG, Vriesema JL et al: Intravesical gemcitabine: a phase 1 and pharmacokinetic study. Eur Urol 2004; 45: Gontero P, Casetta G, Maso G et al: Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC). Eur Urol 2004; 46: Bartoletti R, Cai T, Gacci M et al: Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study. Urology 2005; 66: Serretta V, Galuffo A, Pavone C et al: Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions. Urology 2005; 65: Laufer M, Ramalingam S, Schoenberg MP et al: Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study. J Clin Oncol 2003; 21: Bohle A, Leyh H, Frei C et al: Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study. Eur Urol 2009; 56: Skinner EC, Goldman B, Sakr WA et al: SWOG S0353: Phase II trial of intravesical gemcitabine in patients with non-muscle invasive bladder cancer who recurred following at least two prior courses of BCG. Presented at annual meeting of American Urological Association, Atlanta, Georgia, May 19-23, 2012, abstract Huguet J, Crego M, Sabate S et al: Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 2005; 48: 53.

Management options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center

Management options for high-risk, BCG-refractory NMIBC. Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Management options for high-risk, BCG-refractory NMIBC Alan M. Nieder, M.D. Columbia University Division of Urology Mount Sinai Medical Center Bladder Cancer in U.S. 4 th most common cancer in men 9 th

More information

Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer

Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer Phase 2 Study of Adjuvant Intravesical Instillations of Apaziquone for High Risk Nonmuscle Invasive Bladder Cancer K. Hendricksen,* E. B. Cornel, T. M. de Reijke, H. C. Arentsen, S. Chawla and J. A. Witjes

More information

Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome

Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome DOI 10.1007/s00345-014-1383-5 Original Article Mixed low and high grade non muscle invasive bladder cancer: a histological subtype with favorable outcome Tina Schubert Matthew R. Danzig Srinath Kotamarti

More information

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland

NMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.

More information

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer

The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer The Predictors of Local Recurrence after Radical Cystectomy in Patients with Invasive Bladder Cancer Hiroki Ide, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Takashi Ohigashi, Jun Nakashima and Mototsugu

More information

Reviewing Immunotherapy for Bladder Carcinoma In Situ

Reviewing Immunotherapy for Bladder Carcinoma In Situ Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology

More information

Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity

Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity EUROPEAN UROLOGY 61 (2012) 1025 1030 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Lymph Node Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy:

More information

YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI

YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI KADONO, HIROYUKI KONAKA, ATSUSHI MIZOKAMI and MIKIO NAMIKI Retrospective Analysis of the Efficacy of Two Cycles of M-VAC Neoadjuvant Chemotherapy Followed by Radical Cystectomy for Muscle-invasive Bladder Cancer YASUHIDE KITAGAWA, KOUJI IZUMI, SOTARO MIWA, YOSHIFUMI

More information

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy

Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,

More information

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008

Chemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008 Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation

More information

CUA guidelines on the management of non-muscle invasive bladder cancer

CUA guidelines on the management of non-muscle invasive bladder cancer Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney

More information

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016

Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma

More information

Cancer Drugs Fund. Managed Access Agreement. Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable

Cancer Drugs Fund. Managed Access Agreement. Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable Cancer Drugs Fund Managed Access Agreement Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Cancer Drugs Fund Data

More information

Objectives. Results. Patients and Methods. Conclusions. associated percentages were used to analyse treatment variables.

Objectives. Results. Patients and Methods. Conclusions. associated percentages were used to analyse treatment variables. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscleinvasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette- Guérin (BCG): results of an international

More information

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma

The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell Carcinoma Ivyspring International Publisher Research Paper 686 Journal of Cancer 2013; 4(8): 686-690. doi: 10.7150/jca.7326 The Efficacy of Adjuvant Chemotherapy for Locally Advanced Upper Tract Urothelial Cell

More information

CUA guidelines on the management of non-muscle invasive bladder cancer

CUA guidelines on the management of non-muscle invasive bladder cancer Original cua guidelines research CUA guidelines on the management of non-muscle invasive bladder cancer Wassim Kassouf, MD, CM, FRCSC; * Samer L. Traboulsi, MD; * Girish S. Kulkarni, MD, FRCSC; Rodney

More information

Neodjuvant chemotherapy

Neodjuvant chemotherapy Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional

More information

Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy.

Influence of stage discrepancy on outcome in. in patients treated with radical cystectomy. Tumori, 96: 699-703, 2010 Influence of stage discrepancy on outcome in patients treated with radical cystectomy Ja Hyeon Ku 1, Kyung Chul Moon 2, Cheol Kwak 1, and Hyeon Hoe Kim 1 1 Department of Urology,

More information

Ivyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract

Ivyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract 2885 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(15): 2885-2891. doi: 10.7150/jca.20003 Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT:

More information

better time to first recurrence compared to no adjuvant treatment. 1 3 Previous large randomized clinical trials performed

better time to first recurrence compared to no adjuvant treatment. 1 3 Previous large randomized clinical trials performed 0022-5347/00/1634-1124/0 THE JOURNAL OF UROLOGY Vol. 163, 1124 1129, April 2000 Copyright 2000 by AMERICAN UROLOGICAL ASSOCIATION, INC. Printed in U.S.A. MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY

More information

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer

Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer The new england journal of medicine original article Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer H. Barton Grossman, M.D., Ronald B. Natale,

More information

Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer

Bladder Preservation Protocols in the Treatment of Muscle-Invasive Bladder Cancer Bladder-preserving therapy is a safe and effective alternative to cystectomy for carefully selected patients with bladder cancer. Michael Mahany. Trumpeter Swans on Byer s Lake. Photograph. Denali National

More information

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause. CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase

More information

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current

More information

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer bs_bs_banner Asia-Pacific Journal of Clinical Oncology 2013; 9: 310 317 doi: 10.1111/ajco.12017 ORIGINAL ARTICLE Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for

More information

european urology 55 (2009)

european urology 55 (2009) european urology 55 (2009) 911 921 available at www.sciencedirect.com journal homepage: www.europeanurology.com Bladder Cancer Bladder Preservation in Selected Patients with Muscle-Invasive Bladder Cancer

More information

Urinary Bladder Cancer

Urinary Bladder Cancer Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b

More information

1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC.

1. Introduction. 2. Methods. high-risk NMIBC in men with and without a prior history of RT for PC. ISRN Urology Volume 2013, Article ID 405064, 5 pages http://dx.doi.org/10.1155/2013/405064 Research Article Radical Cystectomy after BCG Immunotherapy for High-Risk Nonmuscle-Invasive Bladder Cancer in

More information

Non Muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer Non-Muscle-Invasive Bladder Cancer Staging, Treatment and Assessment Featuring SWOG Trials S1602 & S1605 Peter C.V. Black, M.D. S1605 Study Chair University of British Columbia Vancouver Prostate Centre

More information

Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines

Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines Sam S. Chang, MD, MBA Patricia & Rodes Hart Chair Professor of Urologic Surgery & Oncology Vanderbilt University Medical

More information

T1HG Bladder Cancer What is the Best Therapy?

T1HG Bladder Cancer What is the Best Therapy? T1HG Bladder Cancer What is the Best Therapy? Ashish M. Kamat, MD, MBBS, FACS Professor of Urology Director, Urologic Oncology Fellowship Guidelines for T1HG Bladder Cancer AUA Recommendation: BCG induction

More information

Chemotherapy Treatment Algorithms for Urology Cancer

Chemotherapy Treatment Algorithms for Urology Cancer Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional

More information

Effectiveness of A Single Immediate Mitomycin C Instillation in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up

Effectiveness of A Single Immediate Mitomycin C Instillation in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up Journal of the Egyptian Nat. Cancer Inst., Vol. 19, No. 2, June: 121-126, 2007 in Patients with Low Risk Superficial Bladder Cancer: Short and Long-Term Follow-up SAMIR EL-GHOBASHY, M.D.; TAREK R. EL-LEITHY,

More information

Treatment of muscle invasive bladder cancer. ie: pt2. N. Mottet

Treatment of muscle invasive bladder cancer. ie: pt2. N. Mottet Treatment of muscle invasive bladder cancer ie: pt2 N. Mottet Disclosures Astellas BMS Pierre Fabre Sanofi MIBC: really undertreated 28 691 MIBC in the US (national database). Gray Eur Urol 2013 Patients

More information

Checkpoint Inibitors for Bladder Cancer

Checkpoint Inibitors for Bladder Cancer Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,

More information

Bone Metastases in Muscle-Invasive Bladder Cancer

Bone Metastases in Muscle-Invasive Bladder Cancer Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer

More information

Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute

Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic

More information

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy

Impact of adjuvant chemotherapy on patients with pathological Stage T3b and/or lymph node metastatic bladder cancer after radical cystectomy Japanese Journal of Clinical Oncology, 2015, 45(10) 963 967 doi: 10.1093/jjco/hyv098 Advance Access Publication Date: 29 July 2015 Original Article Original Article Impact of adjuvant chemotherapy on patients

More information

Clinical Practice Recommendations for the Management of Non Muscle Invasive Bladder Cancer

Clinical Practice Recommendations for the Management of Non Muscle Invasive Bladder Cancer european urology supplements 7 (2008) 651 666 available at www.sciencedirect.com journal homepage: www.europeanurology.com Clinical Practice Recommendations for the Management of Non Muscle Invasive Bladder

More information

Panel: A Case-based Approach to the Management of Bladder Cancer

Panel: A Case-based Approach to the Management of Bladder Cancer Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E.

More information

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION

J Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION VOLUME 23 NUMBER 21 JULY 20 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine,

More information

of Urology, Nagoya Memorial Hospital, Nagoya, Japan Keywords: Urothelial carcinoma, cisplatin, gemcitabine, pathological complete response.

of Urology, Nagoya Memorial Hospital, Nagoya, Japan Keywords: Urothelial carcinoma, cisplatin, gemcitabine, pathological complete response. 188 Journal of Analytical Oncology, 2013, 2, 188-194 Pathological Complete Response Induced by the Combination Therapy of Gemcitabine and 24-h Infusion of Cisplatin in Two Cases Initially Diagnosed as

More information

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015

Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Alicia K. Morgans, MD Assistant Professor of Medicine Division of Hematology/Oncology Vanderbilt University Medical Center January 24, 2015 Overview Background Perioperative chemotherapy in MIBC Neoadjuvant

More information

16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) -

16:30-18:30 WS #67: Urology Forum - Prostate Cancer, Stones, Renal Tumours, Voiding Dysfunction (120 minutes, not repeated) - Dr Anna Lawrence Urologist Auckland Dr Andrew Williams Urologist Auckland Madhu Koya Urologist Auckland Andrew Lienert Urologist Auckland Dr Louise Tomlinson Consultant Gynaecologist Auckland 16:30-18:30

More information

Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer

Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer S86 Efficacy and Safety of Bacille Calmette-Guérin Immunotherapy in Superficial Bladder Cancer Donald L. Lamm Department of Urology, West Virginia University, Morgantown In the United States, bladder cancer

More information

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER

EAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,

More information

A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density

A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma Demonstrating the Usefulness of the Concept of Lymph Node Density Clinical Urology TCC of the Bladder and Lymph Node Density International Braz J Urol Vol. 32 (5): 536-549, September - October, 2006 A Fourteen-Year Review of Radical Cystectomy for Transitional Cell Carcinoma

More information

Guidelines for the Management of Bladder Cancer

Guidelines for the Management of Bladder Cancer Guidelines for the Management of Bladder Cancer Date Approved by Network Governance July 2012 Date for Review July 2015 Changes Between Version 3 and 4 Sections 5.2 and 8 updated Page 1 of 9 1. Scope of

More information

symposium article introduction symposium article

symposium article introduction symposium article Annals of Oncology 17 (Supplement 5): v118 v122, 2006 doi:10.1093/annonc/mdj965 Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/ vinblastine/doxorubicin/cisplatin

More information

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD

Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD Open clinical uro-oncology trials in Canada George Rodrigues, MD, Mary J. Mackenzie, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED

More information

Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer

Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Debate: Adjuvant vs. Neoadjuvant Therapy for Urothelial Cancer Kala Sridhar, MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital GU Medical Oncology Site Group Head Associate Professor, University

More information

Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature

Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature ISPUB.COM The Internet Journal of Urology Volume 7 Number 1 Primary Small Cell Carcinoma Of The Bladder: A Case Report And Review Of The Literature T Hsieh, J Aragon-Ching, J Saia, T Sotelo Citation T

More information

Immunotherapy for Genitourinary Cancers. Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI

Immunotherapy for Genitourinary Cancers. Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI Immunotherapy for Genitourinary Cancers Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI Disclosures Madison Vaccines Inc co-founder, IP, consultant

More information

Case Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case

More information

Let us know how access to this document benefits you

Let us know how access to this document benefits you Thomas Jefferson University Jefferson Digital Commons Department of Urology Faculty Papers Department of Urology 7-2014 Safety of hexaminolevulinate for blue light cystoscopy in bladder cancer. A combined

More information

Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscleinvasive

Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscleinvasive International Journal of Hyperthermia ISSN: 0265-6736 (Print) 1464-5157 (Online) Journal homepage: http://www.tandfonline.com/loi/ihyt20 Intravesical radiofrequency-induced hyperthermia combined with chemotherapy

More information

HHS Public Access Author manuscript Clin Genitourin Cancer. Author manuscript; available in PMC 2017 August 01.

HHS Public Access Author manuscript Clin Genitourin Cancer. Author manuscript; available in PMC 2017 August 01. Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy Derek E. Thomas 1, Hristos Z. Kaimakliotis 1,2, Kevin R. Rice 1,2, Jose A. Pereira

More information

UPDATE: DIAGNOSIS AND TREATMENT OF MUSCLE- INVASIVE AND METASTATIC BLADDER CANCER IN 2014

UPDATE: DIAGNOSIS AND TREATMENT OF MUSCLE- INVASIVE AND METASTATIC BLADDER CANCER IN 2014 UPDATE: DIAGNOSIS AND TREATMENT OF MUSCLE- INVASIVE AND METASTATIC BLADDER CANCER IN 2014 *Johannes Bründl, Philipp J. Spachmann, Maximilian Burger Department of Urology, University of Regensburg, Caritas

More information

A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma

A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma Tai-Tsang Chen, PhD Global Biometric Sciences, Bristol-Myers Squibb EFSPI Statistical Meeting on Evidence Synthesis Brussels, Belgium November

More information

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience

Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Clinical Outcomes of Patients with pt0 Bladder Cancer after Radical Cystectomy: A Single-institute Experience Fumimasa Fukuta, Naoya Masumori *, Ichiya Honma, Masatoshi Muto, Koji Ichihara, Hiroshi Kitamura

More information

Bladder Cancer Guidelines

Bladder Cancer Guidelines Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder

More information

September 10, Dear Dr. Clark,

September 10, Dear Dr. Clark, September 10, 2015 Peter E. Clark, MD Chair, NCCN Bladder Cancer Guidelines (Version 2.2015) Associate Professor of Urologic Surgery Vanderbilt Ingram Cancer Center Nashville, TN 37232 Dear Dr. Clark,

More information

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers

Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers 日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu

More information

UC San Francisco UC San Francisco Previously Published Works

UC San Francisco UC San Francisco Previously Published Works UC San Francisco UC San Francisco Previously Published Works Title High-risk nonmuscle invasive bladder cancer: Definition and epidemiology Permalink https://escholarship.org/uc/item/11p2k07q Journal Current

More information

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer

Some Seminal Studies. Chemotherapy Alone is Inadequate. Bladder Cancer Role of Radiation in Bladder Sparing. Primary Radiation for Bladder Cancer Bladder Cancer Role of Radiation in Bladder Sparing David C. Beyer M.D., FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Primary Radiation for Bladder Cancer No modern surgery / XRT randomized

More information

Supplementary Appendix to manuscript submitted by Trappe, R.U. et al:

Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful

More information

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre

CHEMO-RADIOTHERAPY FOR BLADDER CANCER. Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre CHEMO-RADIOTHERAPY FOR BLADDER CANCER Dr Darren Mitchell Consultant Clinical Oncologist Northern Ireland Cancer Centre AIMS Muscle invasive disease Current Gold-Standard Rationale behind Chemo-Radiotherapy

More information

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto

Koji Ichihara Hiroshi Kitamura Naoya Masumori Fumimasa Fukuta Taiji Tsukamoto Int J Clin Oncol (2013) 18:75 80 DOI 10.1007/s10147-011-0346-8 ORIGINAL ARTICLE Transurethral prostate biopsy before radical cystectomy remains clinically relevant for decision-making on urethrectomy in

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Beware the BCG Failures: A Review of One Institution's Results

Beware the BCG Failures: A Review of One Institution's Results European Urology European Urology 42 (2002) 542±546 Beware the BCG Failures: A Review of One Institution's Results C. Richard W. Lockyer a,*, James E.C. Sedgwick b, David A. Gillatt a a Bristol Urological

More information

The Motion: Perioperative Chemotherapy in Muscle Invasive Bladder Cancer Improves Survival

The Motion: Perioperative Chemotherapy in Muscle Invasive Bladder Cancer Improves Survival with metastatic breast and colorectal cancer who are treated with chemotherapy. In breast, lung and colorectal cancer, the value of early chemotherapy in operable localized and locally advanced disease

More information

Disclosures. Prostate and Bladder Cancer: Jonathan E. Rosenberg, M.D. U.S. Cancer Statistics: Prostate Cancer Known Risk Factors

Disclosures. Prostate and Bladder Cancer: Jonathan E. Rosenberg, M.D. U.S. Cancer Statistics: Prostate Cancer Known Risk Factors Prostate and Bladder Cancer: 2012 Jonathan E. Rosenberg, M.D. Associate Attending Section Head, Non-Prostate Genitourinary Oncology Service Memorial Sloan-Kettering Cancer Center Disclosures Consulting

More information

Neoadjuvant chemotherapy for bladder cancer: fighting between evidence 1 level and real life.

Neoadjuvant chemotherapy for bladder cancer: fighting between evidence 1 level and real life. THE INTERNATIONAL CONFERENCE PROGRESS IN URO-ONCOLOGY 5th Edition September, 25th 26th 2014 CLUJ-NAPOCA Neoadjuvant chemotherapy for bladder cancer: fighting between evidence 1 level and real life. Dr.

More information

Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC

Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC Gary Scott Friedlander, M.D. Urological Consultants, P.A. A Division of Chesapeake Urology Associates, LLC 9420 Key West Ave, Suite 420, Rockville, MD 20850 2730 University Blvd, West, Suite 516, Wheaton,

More information

Tumors in the Randomized German AIO study KRK-0306

Tumors in the Randomized German AIO study KRK-0306 FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the

More information

Chemohyperthermia in non-muscle-invasive bladder cancer: An overview of the literature and recommendations

Chemohyperthermia in non-muscle-invasive bladder cancer: An overview of the literature and recommendations International Journal of Hyperthermia ISSN: 0265-6736 (Print) 1464-5157 (Online) Journal homepage: http://www.tandfonline.com/loi/ihyt20 Chemohyperthermia in non-muscle-invasive bladder cancer: An overview

More information

Medical Management of Renal Cell Carcinoma

Medical Management of Renal Cell Carcinoma Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,

More information

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones

More information

Chemo-radiotherapy in muscle invasive bladder cancer. Dr Paula Wells St Bartholomew s Hospital London

Chemo-radiotherapy in muscle invasive bladder cancer. Dr Paula Wells St Bartholomew s Hospital London Chemo-radiotherapy in muscle invasive bladder cancer Dr Paula Wells St Bartholomew s Hospital London Overview Evidence base for cystectomy vs bladder preservation Chemo-radiotherapy vs radiotherapy alone

More information

Synopsis. Study Phase and Title: Study Objectives: Overall Study Design

Synopsis. Study Phase and Title: Study Objectives: Overall Study Design Synopsis Study Phase and Title: Study Objectives: Overall Study Design Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib

More information

Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma

Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI

More information

Long-term Survival of Extremely Advanced Prostate Cancer Patients Diagnosed with Prostate-specific Antigen over 500 ng/ml

Long-term Survival of Extremely Advanced Prostate Cancer Patients Diagnosed with Prostate-specific Antigen over 500 ng/ml Jpn J Clin Oncol 2014;44(12)1227 1232 doi:10.1093/jjco/hyu142 Advance Access Publication 19 September 2014 Long-term Survival of Extremely Advanced Prostate Cancer Patients Diagnosed with Prostate-specific

More information

Perspective on cytoreduction and metastasis-directed therapy in node positive and metastatic urothelial carcinoma of the bladder

Perspective on cytoreduction and metastasis-directed therapy in node positive and metastatic urothelial carcinoma of the bladder Perspective Perspective on cytoreduction and metastasis-directed therapy in node positive and metastatic urothelial carcinoma of the bladder Karel Decaestecker 1, Valérie Fonteyne 2, Willem Oosterlinck

More information

Renal Pelvis Squamous Cell Carcinoma and Renal Cell Carcinoma in a Tuberculous Kidney

Renal Pelvis Squamous Cell Carcinoma and Renal Cell Carcinoma in a Tuberculous Kidney Case Study TheScientificWorldJOURNAL (2004) 4, 965 968 ISSN 1537-744X; DOI 10.1100/tsw.2004.196 Renal Pelvis Squamous Cell Carcinoma and Renal Cell Carcinoma in a Tuberculous Kidney M. Al-Assiri 1, M.F.

More information

Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy

Sergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26

More information

Bladder cancer comprises 5% of new

Bladder cancer comprises 5% of new : Diagnosis and Treatment KATHARINE C. DeGEORGE, MD, MS; HARRY R. HOLT, MD; and STEPHANIE C. HODGES, MD University of Virginia School of Medicine, Charlottesville, Virginia Bladder cancer is the sixth

More information

BLADDER HEALTH. Non-Muscle Invasive Bladder Cancer: A Patient Guide

BLADDER HEALTH. Non-Muscle Invasive Bladder Cancer: A Patient Guide BLADDER HEALTH Non-Muscle Invasive Bladder Cancer: A Patient Guide Table of Contents Non-Muscle Invasive Bladder Cancer Expert Panel Patient Story.... Introduction.... GET THE FACTS What is bladder cancer?....

More information

Heather Wakelee, M.D.

Heather Wakelee, M.D. Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.

More information

Adjuvant Therapies in Endometrial Cancer. Emma Hudson

Adjuvant Therapies in Endometrial Cancer. Emma Hudson Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial

More information

REVIEW. Abstract. Pathology. Introduction. Initial resection. Repeat resection. Kenneth G. Nepple, MD; Michael A. O Donnell, MD

REVIEW. Abstract. Pathology. Introduction. Initial resection. Repeat resection. Kenneth G. Nepple, MD; Michael A. O Donnell, MD REVIEW The optimal management of T1 high-grade bladder cancer Kenneth G. Nepple, MD; Michael A. O Donnell, MD Abstract Stage T1Hg bladder cancer should be considered an aggressive and potentially lethal

More information

The role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy

The role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David

More information

Media Release. Basel, 21 July 2017

Media Release. Basel, 21 July 2017 Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential

More information

A flowgraph model for bladder carcinoma

A flowgraph model for bladder carcinoma A flowgraph model for bladder carcinoma Gregorio Rubio 1, Belén García-Mora 1, Cristina Santamaría 1, and José Luis Pontones 2 1 Instituto de Matemática Multidisciplinar. Universidad Politécnica de Valencia

More information

ORIGINAL ARTICLE. World J Urol (2011) 29: DOI /s

ORIGINAL ARTICLE. World J Urol (2011) 29: DOI /s World J Urol (2011) 29:487 494 DOI 10.1007/s00345-011-0645-8 ORIGINAL ARTICLE Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial

More information